In a CNBC segment yesterday, Bespoke’s Paul Hickey discussed a recent analysis we did of high flying IPOs and how they compared to other hot IPOs from the past. If you did not see the segment, you can see it via this link. While it is hard to purchase a recent IPO that has already more than tripled in just a few months, we looked through the charts of all relatively new IPOs and found a number of interesting charts. Unfortunately, many of these new issues are in the biotech sector and have little in the way of current or future earnings at this point. Therefore, unless you have some intimate knowledge of the specific treatment the company produces, it’s hard to make an informed decision.
In today’s Chart of the Day, which was sent to paid subscribers, we highlighted three non-biotech off the radar IPOs that looked interesting from both a technical and fundamental perspective. Interestingly, each of the three names also stands to benefit from a major demographic shift taking place within the US population. To see the full report, start a two-week free trial to our premium research product below.